Press Releases Lytix Biopharma

Equities

LYTIX

NO0010405780

Real-time Oslo Bors Other stock markets 05:13:07 2024-05-07 am EDT			5-day change	1st Jan Change
5.58 ^NOK	0.00%		-0.36%	+14.81%

Apr. 25	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI
Apr. 10	Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Correction in the notice of Annual General Meeting in Lytix Biopharma AS	May. 03	AQ
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024	Apr. 30	AQ
Lytix Biopharma AS: Annual Report for 2023	Apr. 30	AQ
Lytix Biopharma AS - Share issue pursuant to board authorisation	Apr. 26	AQ
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates	Apr. 25	AQ
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering	Apr. 25	AQ
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity	Apr. 25	AQ
Lytix Biopharma AS - Preliminary results in the share offering	Apr. 24	AQ
Lytix Biopharma AS - Last day of the Application Period	Apr. 24	AQ
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB	Apr. 22	PU
Lytix Biopharma presents third quarter 2023 results	Nov. 09	AQ
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November	Nov. 08	AQ
Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023	23-10-23	AQ
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from 'SkatteFUNN'	23-10-17	AQ
Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting	23-10-09	AQ
Lytix Biopharma presents first half and second quarter 2023 results	23-08-31	AQ
Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial	23-08-28	AQ
Lytix Biopharma : Redeye interviewed Øystein Rekdal about Lytix and his role as CEO	23-08-18	PU
Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315	23-08-11	AQ
Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting	23-08-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lytix Biopharma

Equities

LYTIX

NO0010405780

Press Releases

Filters